论文部分内容阅读
目的探讨稳心颗粒联合β受体阻断剂治疗冠心病心律失常的临床疗效与安全性。方法选取我院于2013年7月至2015年7月收治的冠心病心律失常患者100例,并随机分为观察组(n=50)和对照组(n=50),对照组单纯给予β受体阻断剂酒石酸美托洛尔进行治疗,观察组则在对照组的基础上,加用稳心颗粒。比较两组患者的临床疗效,治疗前后心律失常改善情况,12导联心电图ST段压低高度以及不良反应情况。结果⑴观察组患者的治疗总有效率为86%,显著高于对照组的70.0%(P<0.05)。⑵治疗后,观察组室性期前收缩和房性期前收缩情况均低于对照组(P<0.05)。结论稳心颗粒联合β受体阻断剂治疗冠心病心律失常效果理想,可有效缓解临床症状,减少并发症,值得在临床中进一步推广。
Objective To investigate the clinical efficacy and safety of Wenxin Granule combined with β-blocker in the treatment of arrhythmia of coronary heart disease. Methods One hundred patients with coronary heart disease and arrhythmia admitted in our hospital from July 2013 to July 2015 were randomly divided into observation group (n = 50) and control group (n = 50), while those in control group were given β Body blocker metoprolol tartrate for treatment, the observation group was in the control group, based on the addition of Wenxin particles. The clinical efficacy, improvement of arrhythmia before and after treatment, ST-segment depression of 12-lead electrocardiogram and adverse reactions were compared between the two groups. Results The total effective rate of observation group was 86%, which was significantly higher than that of control group (70.0%, P <0.05). ⑵ After treatment, the observation group before ventricular contraction and atrial contraction were lower than the control group (P <0.05). Conclusion Wenxin granule combined with β-blocker is effective in treating arrhythmia of coronary heart disease, which can effectively relieve clinical symptoms and reduce complications and is worth further promotion in clinic.